Sinclair Pharma PLC (LON:SPH) has been assigned a consensus recommendation of “Buy” from the five brokerages that are covering the stock. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued a report on the stock in the last year is GBX 62 ($0.81).
A number of analysts recently weighed in on SPH shares. Stifel Nicolaus upped their target price on shares of Sinclair Pharma PLC from GBX 49 ($0.64) to GBX 63 ($0.82) and gave the stock a “buy” rating in a research note on Wednesday, September 14th. Peel Hunt upped their target price on shares of Sinclair Pharma PLC from GBX 66 ($0.86) to GBX 68 ($0.89) and gave the stock a “buy” rating in a research note on Thursday, September 1st. Jefferies Group cut their target price on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating on the stock in a research note on Wednesday, June 15th. N+1 Singer restated a “buy” rating on shares of Sinclair Pharma PLC in a research note on Wednesday, September 21st. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Sinclair Pharma PLC in a research note on Thursday, September 15th.
Sinclair Pharma PLC (LON:SPH) opened at 28.25 on Tuesday. The stock’s 50 day moving average is GBX 29.11 and its 200 day moving average is GBX 32.18. Sinclair Pharma PLC has a 12-month low of GBX 26.25 and a 12-month high of GBX 61.33. The stock’s market capitalization is GBX 140.40 million.
About Sinclair Pharma PLC
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.